Navigation Links
Watson's Generic Yaz(R) Receives FDA Approval
Date:11/29/2011

PARSIPPANY, N.J., Nov. 29, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product.  Watson is currently involved in patent litigation with Bayer concerning this product. 

Yaz(R) had total U.S. sales of $173 million for the twelve months ending September 30, 2011, according to IMS Health. Watson's Vestura(TM) is indicated for the prevention of pregnancy and for the treatment of moderate acne in women at least 14 years old only if the patient desires an oral contraceptive for birth control.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

YAZ(R) is a registered trademark of Bayer Schering Pharma Aktiengesellschaft.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO ) CONTACTS:Investors: 

Patty Eisenhaur 

(862) 261-8141 Media: 

Charlie Mayr 

(862) 261-8030


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
2. Mylan Launches Generic Version of Percodan® Tablets
3. Mylan Launches Generic Version of Sandostatin®
4. Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
5. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
6. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
7. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
8. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
9. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
11. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):